ABBOTT LABORATORIES Aktie

 

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors....

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement....

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch....

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?...

GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results....

SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breachthat led to unauthorized access to the sensitive information of patients affiliated with Abbott Laboratories ("Abbott"), an Illinois-based healthcare and medical device company, and......

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth....

JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?...

TEMPE, Ariz.--(BUSINESS WIRE)--21st Century Healthcare, Inc. ("21st Century" or the "Company"), a leading manufacturer of vitamins, minerals, and supplements, and a portfolio company of Grant Avenue Capital LLC ("Grant Avenue"), a healthcare-focused, middle-market private equity firm, today announced the appointment of Katie Doyle to its Board of Directors. Ms. Doyle brings over 30 years of experience leading and advising consumer health and wellness companies. She most recently served as Executive Chair of FoodScience Corporation, a manufacturer of nutritional supplements with branded, private label, and co-manufacturing lines of business. Prior to FoodScience, Ms. Doyle was Chief Executive Officer of Swanson Health, a private equity-backed e-commerce health and wellness business, and Senior Vice President and Corporate Officer at Abbott Laboratories, where she led the Abbott Nutrition Products Division responsible for a $3.2 billion portfolio of consumer health brands. Ms. ...

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care....

NORTH CHICAGO (dpa-AFX) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid or......

Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to be acquired by Eli Lilly; and Abbott, after reporting second-quarter results and providing an upbeat outlook, among others....

Monatelang wollten Investoren von Abbott Laboratories nichts wissen, die Aktie fiel auf ein neues Mehrjahrestief. Jetzt meldet sie sich eindrucksvoll zurück....

Monatelang wollten Investoren von Abbott Laboratories nichts wissen, die Aktie fiel auf ein neues Mehrjahrestief. Jetzt meldet sie sich eindrucksvoll zurück....

ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness....

Der Top-Market-Mover in den USA ist am heutigen Börsentag überraschend die Pharmafirma Abbott Laboratories. Mehr als zehn Prozent schießen die Papiere nach oben. Doch auf den zweiten Blick erklärt sich, warum der Kurs so stark ansteigt wie seit 24 Jahren nicht mehr....

Shares of Abbott Laboratories were gaining around 11 percent in the early morning trading on the NYE, after the medical devices and health care company on Thursday said it has raised fiscal 2026 adjusted earnings outlook, despite reporting sharply lower profit in its second quarter. The firm recorded higher net sales in the quarter and maintained fiscal 2026 comparable sales view....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...